A compound of Formula or a stereoisomeric form or a tautomer thereof, wherein R 1 is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1-4 alkyl, mono-haloC 1-4 alkyl, poly-halo-C 1-4 alkyl, -CN, and C 3-7 cycloalkyl; R 2 is selected from the group consisting of H; C 1-4 alkyl; C 3-7 cycloalkyl; -CN; -NR a R b; -C NR c R d; -C C 1-4 alkyl; -C 1-4 alkyl-OH; -C 1-4 alkyl-O-C 1-4 alkyl; Aryl; Het; and C 1-4 alkyl substituted with one or more substituents each independently selected from the group consisting of halo and C 3-7 cycloalkyl; wherein R a, R b, R c, and R d are each independently selected from H and C 1-4 alkyl; Aryl is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1-4 alkyl, mono-haloC 1-4 alkyl, and poly-halo-C 1-4 alkyl; Het is (a) a 6-membered aromatic heterocyclyl substituent selected from the group consisting of pyridinyl, and pyrazinyl, each of which may be optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1-4 alkyl, and -NR e R f; or (b) a 5-membered aromatic heterocyclyl selected from the group consisting of thiazolyl, oxazolyl, 1H -pyrazolyl, and 1H -imidazolyl, each of which may be optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1-4 alkyl, mono-haloC 1-4 alkyl, and poly-halo-C 1-4 alkyl; R e and R f are each independently selected from hydrogen, and C 1-4 alkyl; R 3 is selected from the group consisting of hydrogen, halo, C 1-4 alkyl, C 3-7 cycloalkyl, -CN, and -OC 1-4 alkyl; R 4 is selected from hydrogen and C 1-4 alkyl; and R 5 is selected from the group consisting of hydrogen, C 1-4 alkyl, and -C 1-4 alkyl-O-C 1-4 alkyl; or an N-oxide, or a pharmaceutically acceptable salt or a solvate thereof. R 1 is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1-4 alkyl, mono-haloC 1-4 alkyl, poly-halo-C 1-4 alkyl, -CN, and C 3-7 cycloalkyl; R 2 is selected from the group consisting of H; C 1-4 alkyl; C 3-7 cycloalkyl; -CN; -NR a R b; -C NR c R d; -C C 1-4 alkyl; -C 1-4 alkyl-OH; -C 1-4 alkyl-O-C 1-4 alkyl; Aryl; Het; and C 1-4 alkyl substituted with one or more substituents each independently selected from the group consisting of halo and C 3-7 cycloalkyl; wherein R a, R b, R c, and R d are each independently selected from H and C 1-4 alkyl; Aryl is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1-4 alkyl, mono-haloC 1-4 alkyl, and poly-halo-C 1-4 alkyl; Het is (a) a 6-membered aromatic heterocyclyl substituent selected from the group consisting of pyridinyl, and pyrazinyl, each of which may be optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1-4 alkyl, and -NR e R f; or (b) a 5-membered aromatic heterocyclyl selected from the group consisting of thiazolyl, oxazolyl, 1H -pyrazolyl, and 1H -imidazolyl, each of which may be optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1-4 alkyl, mono-haloC 1-4 alkyl, and poly-halo-C 1-4 alkyl; R e and R f are each independently selected from hydrogen, and C 1-4 alkyl; R 3 is selected from the group consisting of hydrogen, halo, C 1-4 alkyl, C 3-7 cycloalkyl, -CN, and -OC 1-4 alkyl; R 4 is selected from hydrogen and C 1-4 alkyl; and R 5 is selected from the group consisting of hydrogen, C 1-4 alkyl, and -C 1-4 alkyl-O-C 1-4 alkyl;